AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03264586
Drug: mepivacaine infiltration group
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic
Trial: NCT04357535
Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
Trial: NCT00132392
Drug: ALGRX 4975
RxNorm normalized name: ALGRX 1207
DrugBank: ALGRX 1207 (DB06482)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006016
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00949182
Drug: sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
Trial: NCT04567069
Drug: Sintilimab Injection
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
Trial: NCT00647517
Drug: Ultracet
RxNorm normalized name: Ultracet
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day.
Trial: NCT00564538
Drug: anti-thymocyte globulin (rabbit)
RxNorm normalized name: anti-thymocyte globulin (rabbit)
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
Trial: NCT00564538
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus will be administered orally on post op day #1 as per standard of care.
Trial: NCT00266695
Drug: Ruboxistaurin
RxNorm normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
Trial: NCT00003606
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003606
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003606
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02610231
Drug: Istradefylline 20 mg or 40 mg
RxNorm normalized name: istradefylline 20 MG
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Istradefylline 20 or 40 mg
Trial: NCT00266149
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00266149
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02850276
Drug: Pyridostigmine
RxNorm normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03642873
Drug: Hydrocodone Bitartrate
RxNorm normalized name: Hydrocodone Bitartrate
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone Bitartrate (3.33 mg q4h X 3)
Trial: NCT02918331
Drug: Daratumumab (16 mg/kg)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
Trial: NCT02918331
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
Trial: NCT02918331
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
Trial: NCT03355976
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240mg flat dose every 2 weeks
Trial: NCT03355976
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 1mg/kg every 6 weeks
Trial: NCT00425035
Drug: Panitumumab (ABX-EGF)
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02234843
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
Trial: NCT02234843
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
Trial: NCT00004100
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004100
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004100
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03889925
Drug: Hyaluronan
RxNorm normalized name: hyaluronan
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
Trial: NCT03217747
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01914510
Drug: ENMD-2076
RxNorm normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01729481
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² iv weekly
Trial: NCT01729481
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg, once per day
Trial: NCT01729481
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85mg/m², q2weeks
Trial: NCT01643499
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01643499
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02959229
Drug: Lactoferrin
RxNorm normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00670046
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given orally
Trial: NCT01108003
Drug: broccoli sprout extract
RxNorm normalized name: broccoli sprout extract
DrugBank: Broccoli (DB10511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02620839
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02620839
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02652585
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01729481
Drug: Folinic Acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m², q2weeks
Trial: NCT01729481
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m², q2weeks
Trial: NCT01729481
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
Trial: NCT03453346
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Generic sofosbuvir tablet 400 mg
Trial: NCT03453346
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin was provided in 100-mg tablets.
Trial: NCT01592110
Drug: risperidone-SABER
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
Trial: NCT02531841
Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)
Trial: NCT02531841
Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
RxNorm normalized name: Tepadina
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)
Trial: NCT00086359
Drug: Abacavir sulfate, lamivudine, and zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one pill twice daily
Trial: NCT00086359
Drug: Lamivudine/zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one pill twice daily
Trial: NCT00086359
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: four pills twice daily
Trial: NCT01592110
Drug: risperidone-SABER
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
Trial: NCT01592110
Drug: Risperidone-SABER
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
Trial: NCT01278810
Drug: Icaritin
RxNorm normalized name: Icaritin
DrugBank: Icaritin (DB12672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
Trial: NCT00650104
Drug: Ropinirole XL (formerly CR)
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
Trial: NCT04251169
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be administered as 30 minutes IV infusion every 3 weeks beginning in Cycle 1
Trial: NCT04251169
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
Trial: NCT01951170
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
Trial: NCT04512482
Drug: Bromelain
RxNorm normalized name: Bromelain
DrugBank: Bromelains (DB13281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
Trial: NCT01078779
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
Trial: NCT00067496
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01913691
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
Trial: NCT03919773
Drug: IVIG
RxNorm normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each.
Trial: NCT03919773
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be the matching placebo used in the study.
Trial: NCT00175812
Drug: all-trans retinoic acid (ATRA)
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
Trial: NCT00175812
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid, highest dose without side effects from day 3 until progression
Trial: NCT00175812
Drug: Theophyllin
RxNorm normalized name: Theophyllin
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophyllin, targetted serum level 50-100 from day 3 until progression
Trial: NCT00415402
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01296815
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
Trial: NCT00414024
Drug: Tegaserod
RxNorm normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01154192
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
Trial: NCT01154192
Drug: recombinant human chorionic gonadotropin (r-hCG)
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
Trial: NCT00054210
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00054210
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00054210
Drug: paclitaxel poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00257075
Drug: Risperidone, oral tablets
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00775294
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
Trial: NCT00374959
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01071057
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
Trial: NCT01071057
Drug: Saline/Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
Trial: NCT03844555
Drug: Elafibranor
RxNorm normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg oral single dose
Trial: NCT02067806
Drug: 2-chloroprocaine hydrochloride, 1%
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
Trial: NCT01158885
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
Trial: NCT01158885
Drug: Cytarabine intravenous
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
Trial: NCT01350999
Drug: omega-3-acid ethyl esters 90 (TAK-085)
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
Trial: NCT00879021
Drug: Lyrica
RxNorm normalized name: Lyrica
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
Trial: NCT02312557
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO